<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03468686</url>
  </required_header>
  <id_info>
    <org_study_id>4748</org_study_id>
    <nct_id>NCT03468686</nct_id>
  </id_info>
  <brief_title>The Study of Effectiveness of rTMS on Rumination and Anhedonia in Patients With Major Depressive Disorder</brief_title>
  <official_title>The Study of Effectiveness of Unilateral and Bilateral Repetitive Transcranial Magnetic Stimulation (rTMS) on Rumination and Anhedonia in Patients With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tehran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Tehran</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the effect of unilateral and bilateral rTMS on the reduction of&#xD;
      rumination and anhedonia and their associated neural networks. In a randomized double-blind&#xD;
      trial, 65 patients with depressive disorder in Atieh Clinical Neuroscience Center are&#xD;
      assigned to three groups. The first group receives bilateral rTMS for 20 sessions on right&#xD;
      and left DLPFC; the second group receives unilateral rTMS for 20 sessions on LDLPFC; third&#xD;
      group receives sham rTMS for 10 sessions. In this group, the stimulation parameters are&#xD;
      similar to that in the actual rTMS group, except that the coil angel is 90° and perpendicular&#xD;
      to the head. Rumination and anhedonia symptoms will be measured by the Ruminative Responses&#xD;
      Scale (RRS) and Snaith-Hamilton Pleasure Scale (SHAPS) in the baseline and after the 20th&#xD;
      session. In order to investigate the neural networks associated with rumination and&#xD;
      anhedonia, EEG of patients will be recorded at the first session and at the end of the&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2016</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rumination Symptoms</measure>
    <time_frame>baseline before start of treatment and immediately after the last treatment session.</time_frame>
    <description>The Ruminative Responses Scale (RRS) is a measure of depressive rumination which has two subscales: Both subscales are composed of five items. Brooding and Reflection. Higher score indicate a higher level of ruminative responses (range: 22-88).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>changes in default mode network</measure>
    <time_frame>baseline before start of treatment and immediately after the last treatment session.</time_frame>
    <description>EEG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anhedonia Symptoms</measure>
    <time_frame>baseline before start of treatment and immediately after the last treatment session.</time_frame>
    <description>Snaith-Hamilton Pleasure Scale (SHAPS), a measure of anhedonia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Depressive symptoms measured by the 17-item Hamilton Depression Rating Scale</measure>
    <time_frame>baseline before start of treatment and immediately after the last treatment session.</time_frame>
    <description>Hamilton Depression Rating Scale (HDRS),(HRSD17) Range: 0-53 Normal: 0-7 Mild: 8 - 13 Moderate 14 - 18 Severe: 19-22 Very severe &gt; 22</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depressive symptoms measured by the 21-item Beck Depression Inventory-II</measure>
    <time_frame>baseline before start of treatment and immediately after the last treatment session.</time_frame>
    <description>Beck Depression Inventory-II (BDI-II), (BDI-II) Range: 0-63 Normal: 0-13 Mild: 14- 9 Moderate 20- 28 Severe: 29-63</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Bipolar Depression</condition>
  <arm_group>
    <arm_group_label>bilateral rTMS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sequential bilateral repetitive Transcranial Magnetic Stimulation (rTMS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham rTMS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham Transcranial Magnetic Stimulation (rTMS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unilateral rTMS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Unilateral (High frequency) repetitive Transcranial Magnetic Stimulation (rTMS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bilateral rTMS</intervention_name>
    <description>The coil will locate on F3 and F4 in accordance with the 10-20 international system. bilateral rTMS include stimulate the right DLPFC at 1 Hz for a 10 seconds train of stimulation, and a total of 150 pulse trains. Immediately after that, the stimulation was carried out on the left DLPFC at 10 Hz, 5 seconds of stimulation, with 10 second inter-train interval and 75 pulse trains.</description>
    <arm_group_label>bilateral rTMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham rTMS</intervention_name>
    <description>The same parameters will use in the sham rTMS. However, the coil adjust at an angle of 90º vertically on the skull in a way that one wing place on the head.</description>
    <arm_group_label>Sham rTMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Unilateral rTMS (High frequency)</intervention_name>
    <description>The coil will locate on F3 in accordance with the 10-20 international system. Unilateral rTMS include stimulate the Left DLPFC at 10Hz for a 5seconds train of stimulation, 10 seconds inter-train interval, and a total of 75 pulse trains. .</description>
    <arm_group_label>Unilateral rTMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Outpatients male and female with the range of 18-65 years of age&#xD;
&#xD;
          -  The diagnosis of Major depressive disorder according to DSM-V&#xD;
&#xD;
          -  Having BDI&gt;18&#xD;
&#xD;
          -  Having stable symptoms as defined by not requiring a change in medication for at least&#xD;
             4 weeks&#xD;
&#xD;
          -  Completion of consent form&#xD;
&#xD;
          -  Being under supervision of a psychiatrist&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The history of rTMS treatment for any reason&#xD;
&#xD;
          -  Cardiac pacemaker&#xD;
&#xD;
          -  The risk of seizure with any reasons&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  High risk of suicide&#xD;
&#xD;
          -  Intracranial implant and other ferromagnetic materials close to the head&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Kazemi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Atieh Clinical Neuroscience center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reza Kazemi, PhD</last_name>
    <phone>00982184012841</phone>
    <email>rezakazemi@ut.ac.ir</email>
  </overall_contact>
  <location>
    <facility>
      <name>Atieh Clinical Neuroscience Center (ACNC)</name>
      <address>
        <city>Tehran</city>
        <zip>1969713663</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reza Rostami, MD</last_name>
      <phone>009802184012101</phone>
      <email>rrostami@ut.ac.ir</email>
    </contact>
    <investigator>
      <last_name>Reza Rostami, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reza Kazemi, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 6, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Tehran</investigator_affiliation>
    <investigator_full_name>reza kazemi</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <keyword>MDD</keyword>
  <keyword>rTMS</keyword>
  <keyword>Rumination</keyword>
  <keyword>Anhedonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rumination Syndrome</mesh_term>
    <mesh_term>Anhedonia</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

